Editas Medicine Inc Asset Resilience Ratio
Editas Medicine Inc asset resilience ratio. Editas Medicine Inc (EDIT) has an Asset Resilience Ratio of 12.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Editas Medicine Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Editas Medicine Inc (2015–2025)
Asset resilience ratio of Editas Medicine Inc from 2015 to 2025. This chart shows how Editas Medicine Inc's Asset Resilience Ratio has changed over time. Read Editas Medicine Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Editas Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Editas Medicine Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.83 Million | 12.57% |
| Total Liquid Assets | $29.83 Million | 12.57% |
Asset Resilience Insights
- Moderate Liquidity: Editas Medicine Inc has 12.57% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Editas Medicine Inc Industry Peers by Asset Resilience Ratio
Compare Editas Medicine Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.40% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Editas Medicine Inc Asset Resilience Ratio by Year (2015–2025)
Editas Medicine Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Editas Medicine Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $186.53 Million | -- |
| 2024-12-31 | 40.51% | $138.37 Million | $341.59 Million | +0.55pp |
| 2023-12-31 | 39.96% | $199.46 Million | $499.15 Million | +0.54pp |
| 2022-12-31 | 39.42% | $202.75 Million | $514.32 Million | -4.32pp |
| 2021-12-31 | 43.74% | $296.33 Million | $677.48 Million | -2.09pp |
| 2020-12-31 | 45.83% | $262.43 Million | $572.60 Million | +2.80pp |
| 2019-12-31 | 43.03% | $218.96 Million | $508.88 Million | -12.68pp |
| 2018-12-31 | 55.71% | $234.18 Million | $420.39 Million | +6.81pp |
| 2017-12-31 | 48.90% | $182.51 Million | $373.26 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $229.18 Million | -- |
| 2015-12-31 | 0.21% | $320.00K | $149.36 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more